{
}
Biogen Inc. (NASDAQ:BIIB) offers a range of therapies for neurological and neurodegenerative diseases, including multiple sclerosis and Alzheimer's. Recently, Banco Santander S.A. invested $7.31 million in Biogen, while analysts maintain a "hold" rating on the stock, which has a current price of $150.38 and a market cap of $22.01 billion. The company reported an EPS of $3.44 for the last quarter, slightly above expectations, and anticipates a total EPS of 15.83 for the current year.
Deutsche Bank has adjusted its price target for Denali Therapeutics Inc. to $29 from $31 while maintaining a Buy rating. The biopharmaceutical company focuses on developing therapies that can cross the blood-brain barrier for neurodegenerative and lysosomal storage diseases, with seven clinical candidates in development. Key programs include tividenofusp alfa for MPS II, a LRRK2 inhibitor for Parkinson's disease, and an eIF2B activator for ALS, among others.
The global digital neuro biomarkers market is projected to reach USD 2.82 billion by 2030, growing at a CAGR of 25.7% from 2025, driven by the rising prevalence of neurological disorders and advancements in technology. Key players are focusing on innovative solutions, including AI integration and wearable devices, to enhance patient monitoring and treatment. North America leads the market, accounting for 37.7% of revenue in 2024, as demand for effective diagnostic tools increases.
Investors are keenly observing advancements in Alzheimer’s disease treatments, with significant interest expected in 2025. Companies like Biogen and Eli Lilly have invested heavily in potential therapies, while others such as Novo Nordisk and Roche are also exploring this area. Breakthroughs could significantly influence share prices, as the market is projected to reach $13 billion by 2030, according to Bloomberg Intelligence.
The North America oncology drugs market, valued at USD 10.13 billion in 2023, is projected to grow at a CAGR of 10.38%, reaching USD 27.20 billion by 2033. Key drivers include advances in cancer research, rising cancer prevalence, and increasing demand for personalized medicine, while challenges include high drug costs and stringent regulations. The market is segmented into cytotoxic, targeted, and hormonal drugs, with targeted therapies expected to dominate due to their effectiveness and reduced toxicity.
EpiMonitor, the only FDA-approved portable seizure detection system in the USA, is now available for adults and children aged six and over. The global psychiatric digital biomarkers market is projected to grow significantly, driven by increasing demand for real-time mental health monitoring and the integration of digital solutions in healthcare, particularly in North America and Europe. Key players include Empatica Inc. and Biogen, with ongoing innovations enhancing patient outcomes and treatment personalization.
Switzerland is a prime location for over 850 international companies, primarily from North America and Europe, drawn by its favorable business climate, political stability, and high quality of life. The country offers advantages such as flexible labor laws, a skilled workforce, and an attractive tax environment, making it an ideal hub for global operations and a diverse test market.
The global red biotechnology market is projected to grow from $381.01 billion in 2023 to $699.31 billion by 2033, driven by rising chronic disease prevalence and increased healthcare funding. Key players like Pfizer and Amgen are advancing drug development, particularly in precision medicine, despite high trial failure rates. Recent mergers, such as Ipsen's acquisition of Albireo, highlight ongoing consolidation in the sector.
Roche is considering seeking accelerated U.S. approval for its Alzheimer’s drug trontinemab, which shows promise in significantly lowering amyloid protein levels linked to cognitive decline. Early Phase 2 data indicates it may clear amyloid more quickly than competitors, with fewer side effects like ARIA. The company plans to expand its trial to 120 participants while adjusting safety criteria after a related incident.
Jade Biosciences will merge with Aerovate Therapeutics in a reverse merger, allowing Jade to enter public markets under the ticker “JBIO.” The deal, expected to close in the first half of 2025, includes a $300 million private financing round and will see Jade's shareholders retain over 98% ownership of the combined entity. Jade's lead drug, targeting IgA nephropathy, is set to enter clinical trials in late 2024.
Biogen Inc.
Companies
| Symbol | BIIB |
| Name | Biogen Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | United States |
| State | MA |
| City | Cambridge |
| Zipcode | 2142 |
| Website | http://www.biogen.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
biogen expands portfolio with new treatments and investor interest grows
11:07 09.03.2025
Deutsche Bank lowers Denali Therapeutics price target while maintaining buy rating
13:42 03.03.2025
digital neuro biomarkers market projected to reach 2.82 billion by 2030
15:10 14.01.2025
investors eye alzheimer's drug breakthroughs for potential market gains
06:00 10.01.2025
rth america oncology drugs market projected to reach 27.20 billion by 2033
United States Dollar
Novartis AG
Gilead Sciences, Inc.
Sanofi
Takeda Pharmaceutical Company Limited
Johnson & Johnson
Amgen Inc.
Bristol-Myers Squibb Company
Biogen Inc.
AstraZeneca PLC
Roche Holding AG
Pfizer Inc.
Merck & Co., Inc.
Celgene Corporation
AbbVie Inc.
Eli Lilly and Company
USA
Show more
14:29 22.11.2024
global psychiatric digital biomarkers market poised for significant growth through 2033
United States Dollar
IXICO plc
Biogen Inc.
USA
GBR
AUS
ARG
KOR
CHN
IND
BRA
ITA
MEX
FRA
ESP
ZAF
RUS
JPN
DEU
ARE
CAN
Donald Trump
Biogen Inc.
Joe Biden
Show more
03:54 19.11.2024
Switzerland's appeal for international companies and strategic business advantages
United States Dollar
Johnson & Johnson
Mondelez International, Inc.
DuPont de Nemours, Inc.
Biogen Inc.
Caterpillar Inc.
The Procter & Gamble Company
IBM 401(k) Plan Trust
Google Inc.
Dow Inc.
JPN
CHN
USA
Procter & Gamble
Johnson & Johnson
Mondelez
IBM
Show more
11:14 07.11.2024
global red biotechnology market poised for significant growth by 2033
United States Dollar
Novartis AG
Biogen Inc.
Amgen Inc.
Tesla, Inc.
Pfizer Inc.
CHN
FRA
ESP
BRA
KOR
IND
ZAF
ITA
SAU
ARG
CAN
USA
RUS
JPN
MEX
GBR
DEU
ARE
AUS
QAT
MedTech Acquisition Corporation
Ipsen
TriSalus Vie Sciences
Spheric Insights
Albireo
Show more
23:55 06.11.2024
Roche considers accelerated approval for promising Alzheimer’s drug trontinemab
United States Dollar
Biogen Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Hoffmann-La Roche AG
CHE
Eli Lilly
Hanno Svoboda
Biogen
Eisai
Show more
22:44 31.10.2024
jade biosciences to merge with aerovate in reverse merger deal
United States Dollar
Vertex Pharmaceuticals Incorporated
Travere Therapeutics, Inc.
Calliditas Therapeutics AB
Novartis AG
Biogen Inc.
USA
Tom Frohlich
Andrew King
Show more
17:18 31.10.2024
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Retail and Consumer Goods
Finance Mergers & Acquisitions
Global Financial Events
Industry Mergers & Acquisitions
Global Trade Developments
Banking Regulations
CEO Changes
Market Analysis and Predictions
Central Bank Actions
Supply Chain Management
Workplace Trends
Startups & Entrepreneurship
Government Economic Policies
Energy Sector Developments
Hedge Funds & Private Equity
Financial Scams and Security
Government Policies
Countries:
Companies:
Barclays PLC
BNP Paribas SA
Tesla, Inc.
Deutsche Bank RV Global PP
Apple Inc.
The Goldman Sachs Group, Inc.
Citigroup Inc.
Bank of America Corporation
Raiffeisen Bank International AG
JPMorgan Chase & Co.
Wells Fargo & Company
Alphabet Inc.
UniCredit S.p.A.
UBS Group AG
Strabag SE
Morgan Stanley
Lloyds Banking Group plc
Commerzbank AG
NVIDIA Corporation
Berkshire Hathaway Inc.
Currencies:
United States Dollar
Euro
British Pound Sterling
Chinese Yuan
Swiss Franc
Indian Rupee
Japanese Yen
Vietnamese Đồng
Russian Ruble
Brazilian Real
Canadian Dollar
Hong Kong Dollar
United Arab Emirates Dirham
Australian Dollar
Indonesian Rupiah
South Korean Won
Filipino Peso
Malaysian Ringgit
South African Rand
Offshore Chinese Yuan
People: